%0 Journal Article
%T Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
%A Fritz S£¿rgel
%A Ursula Thyroff-Friesinger
%A Andrea Vetter
%A Bernhard Vens-Cappell
%A Martina Kinzig
%J BMC Pharmacology and Toxicology
%D 2009
%I BioMed Central
%R 10.1186/1472-6904-9-10
%X An open, randomised, parallel group study was conducted in 80 healthy adult males. Subjects were randomised to multiple intravenous doses of 100 IU/kg body weight of HX575 or of the comparator epoetin alfa three-times-weekly for four weeks. Serum epoetin concentrations were measured using an enzyme-linked immunosorbent assay and pharmacokinetic parameters for the two treatments were compared. The time course and area under the effect curve ratio of haematological characteristics were used as surrogate parameters for efficacy evaluation.The haematological profiles of both treatments were similar, as determined from their population mean curves and the AUECHb ratio and 90% confidence interval (99.9% [98.5¨C101.2%]), the primary pharmacodynamic endpoint of this study. The pharmacokinetic parameters after the treatments showed minor differences after single dosing, but not at steady state doses. After multiple doses, HX575 was bioequivalent to the comparator with respect to the rate and extent of exposure of exogenous epoetin (AUC¦Ó ratio and 90% confidence interval: 89.2% [82.5¨C96.2%]). Study medication was well tolerated with no clinically relevant differences between safety profiles of the treatments. Anti-epoetin antibodies were not detected.HX575 and the comparator epoetin alfa were bioequivalent at steady state circulating drug concentrations with respect to their pharmacokinetic profile and pharmacodynamic action. This supports the conclusion that HX575 and the comparator epoetin alfa, when administered intraveneously, will be equally efficacious and may be interchangeable as therapy.Epoetin is a glycoprotein that stimulates red blood cell (RBC) production [1]. Patients with chronic renal failure have impaired epoetin production, which is the primary cause of their anaemia [2,3]. Human recombinant epoetin or erythropoiesis stimulating agents (ESA) has been shown to stimulate erythropoiesis in anaemic patients with chronic renal failure, both in those who do, and th
%U http://www.biomedcentral.com/1472-6904/9/10